当前位置: 首页 >> 检索结果
共有 5672 条符合本次的查询结果, 用时 7.7570398 秒

101. Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.

作者: Timothy L Jackson.;Riti Desai.;Hatem A Wafa.;Yanzhong Wang.;Janet Peacock.;Tunde Peto.;Usha Chakravarthy.;Helen Dakin.;Sarah Wordsworth.;Cornelius Lewis.;Patricia Clinch.;Lisa Ramazzotto.;James E Neffendorf.;Chan Ning Lee.;Joe M O'Sullivan.;Barnaby C Reeves.; .
来源: Lancet. 2024年404卷10447期44-54页
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness. The first-line therapy is anti-vascular endothelial growth factor (anti-VEGF) agents delivered by intravitreal injection. Ionising radiation mitigates key pathogenic processes underlying nAMD, and therefore has therapeutic potential. STAR aimed to assess whether stereotactic radiotherapy (SRT) reduces the number of anti-VEGF injections required, without sacrificing visual acuity.

102. Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial.

作者: Christopher Patrick Bretherton.;Juul Achten.;Vidoushee Jogarah.;Stavros Petrou.;Nicholas Peckham.;Felix Achana.;Duncan Appelbe.;Rebecca Kearney.;Harry Claireux.;Philip Bell.;Xavier L Griffin.; .
来源: Lancet. 2024年403卷10446期2787-2797页
After surgery for a broken ankle, patients are usually instructed to avoid walking for 6 weeks (delayed weight-bearing). Walking 2 weeks after surgery (early weight-bearing) might be a safe and preferable rehabilitation strategy. This study aimed to determine the clinical and cost effectiveness of an early weight-bearing strategy compared with a delayed weight-bearing strategy.

103. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.

作者: Kenneth Chan.;Elizabeth Wahome.;Apostolos Tsiachristas.;Alexios S Antonopoulos.;Parijat Patel.;Maria Lyasheva.;Lucy Kingham.;Henry West.;Evangelos K Oikonomou.;Lucrezia Volpe.;Michail C Mavrogiannis.;Edward Nicol.;Tarun K Mittal.;Thomas Halborg.;Rafail A Kotronias.;David Adlam.;Bhavik Modi.;Jonathan Rodrigues.;Nicholas Screaton.;Attila Kardos.;John P Greenwood.;Nikant Sabharwal.;Giovanni Luigi De Maria.;Shahzad Munir.;Elisa McAlindon.;Yogesh Sohan.;Pete Tomlins.;Muhammad Siddique.;Andrew Kelion.;Cheerag Shirodaria.;Francesca Pugliese.;Steffen E Petersen.;Ron Blankstein.;Milind Desai.;Bernard J Gersh.;Stephan Achenbach.;Peter Libby.;Stefan Neubauer.;Keith M Channon.;John Deanfield.;Charalambos Antoniades.; .
来源: Lancet. 2024年403卷10444期2606-2618页
Coronary computed tomography angiography (CCTA) is the first line investigation for chest pain, and it is used to guide revascularisation. However, the widespread adoption of CCTA has revealed a large group of individuals without obstructive coronary artery disease (CAD), with unclear prognosis and management. Measurement of coronary inflammation from CCTA using the perivascular fat attenuation index (FAI) Score could enable cardiovascular risk prediction and guide the management of individuals without obstructive CAD. The Oxford Risk Factors And Non-invasive imaging (ORFAN) study aimed to evaluate the risk profile and event rates among patients undergoing CCTA as part of routine clinical care in the UK National Health Service (NHS); to test the hypothesis that coronary arterial inflammation drives cardiac mortality or major adverse cardiac events (MACE) in patients with or without CAD; and to externally validate the performance of the previously trained artificial intelligence (AI)-Risk prognostic algorithm and the related AI-Risk classification system in a UK population.

104. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.

作者: Suhaniya N S Samarasinghe.;Bianca Leca.;Shahd Alabdulkader.;Georgios K Dimitriadis.;Allan Davasgaium.;Puja Thadani.;Kate Parry.;Migena Luli.;Karen O'Donnell.;Brett Johnson.;Ali Abbara.;Florian Seyfried.;Rachel Morman.;Ahmed R Ahmed.;Sherif Hakky.;Christos Tsironis.;Sanjay Purkayastha.;Carel W le Roux.;Stephen Franks.;Vinod Menon.;Harpal Randeva.;Alexander D Miras.
来源: Lancet. 2024年403卷10443期2489-2503页
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Obesity exacerbates the reproductive complications of PCOS; however, the management of obesity in women with PCOS remains a large unmet clinical need. Observational studies have indicated that bariatric surgery could improve the rates of ovulatory cycles and prospects of fertility; however, the efficacy of surgery on ovulation rates has not yet been compared with behavioural modifications and medical therapy in a randomised trial. The aim of this study was to compare the safety and efficacy of bariatric surgery versus medical care on ovulation rates in women with PCOS, obesity, and oligomenorrhoea or amenorrhoea.

105. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).

作者: Amanda I Adler.;Ruth L Coleman.;Jose Leal.;William N Whiteley.;Philip Clarke.;Rury R Holman.
来源: Lancet. 2024年404卷10448期145-155页
The 20-year UK Prospective Diabetes Study showed major clinical benefits for people with newly diagnosed type 2 diabetes randomly allocated to intensive glycaemic control with sulfonylurea or insulin therapy or metformin therapy, compared with conventional glycaemic control. 10-year post-trial follow-up identified enduring and emerging glycaemic and metformin legacy treatment effects. We aimed to determine whether these effects would wane by extending follow-up for another 14 years.

106. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.

作者: Chris C Parker.;Noel W Clarke.;Adrian D Cook.;Howard Kynaston.;Charles N Catton.;William R Cross.;Peter M Petersen.;Rajendra A Persad.;Fred Saad.;Lorna C Bower.;John Logue.;Heather Payne.;Silvia Forcat.;Cindy Goldstein.;Claire Murphy.;Juliette Anderson.;Maroie Barkati.;David M Bottomley.;Jennifer Branagan.;Ananya Choudhury.;Peter W M Chung.;Lyn Cogley.;Chee L Goh.;Peter Hoskin.;Vincent Khoo.;Shawn C Malone.;Lindsey Masters.;Stephen L Morris.;Abdenour Nabid.;Aldrich D Ong.;Rakesh Raman.;Kathryn L Tarver.;Alison C Tree.;Jane Worlding.;James P Wylie.;Anjali M Zarkar.;Wendy R Parulekar.;Mahesh K B Parmar.;Matthew R Sydes.; .
来源: Lancet. 2024年403卷10442期2405-2415页
Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear.

107. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.

作者: Chris C Parker.;Howard Kynaston.;Adrian D Cook.;Noel W Clarke.;Charles N Catton.;William R Cross.;Peter M Petersen.;Rajendra A Persad.;Cheryl A Pugh.;Fred Saad.;John Logue.;Heather Payne.;Lorna C Bower.;Chris Brawley.;Mary Rauchenberger.;Maroie Barkati.;David M Bottomley.;Klaus Brasso.;Hans T Chung.;Peter W M Chung.;Ruth Conroy.;Alison Falconer.;Vicky Ford.;Chee L Goh.;Catherine M Heath.;Nicholas D James.;Charmaine Kim-Sing.;Ravi Kodavatiganti.;Shawn C Malone.;Stephen L Morris.;Abdenour Nabid.;Aldrich D Ong.;Rakesh Raman.;Sree Rodda.;Paula Wells.;Jane Worlding.;Wendy R Parulekar.;Mahesh K B Parmar.;Matthew R Sydes.; .
来源: Lancet. 2024年403卷10442期2416-2425页
Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain.

108. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021.

作者: .
来源: Lancet. 2024年403卷10440期2204-2256页
Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050.

109. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

作者: .
来源: Lancet. 2024年403卷10440期2162-2203页
Understanding the health consequences associated with exposure to risk factors is necessary to inform public health policy and practice. To systematically quantify the contributions of risk factor exposures to specific health outcomes, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 aims to provide comprehensive estimates of exposure levels, relative health risks, and attributable burden of disease for 88 risk factors in 204 countries and territories and 811 subnational locations, from 1990 to 2021.

110. Biodiversity and planetary health: a call for integrated action.

作者: Hellas Cena.;Massimo Labra.; .
来源: Lancet. 2024年403卷10440期1985-1986页

111. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial.

作者: Jürgen Beck.;Christian Fung.;Daniel Strbian.;Lukas Bütikofer.;Werner J Z'Graggen.;Matthias F Lang.;Seraina Beyeler.;Jan Gralla.;Florian Ringel.;Karl Schaller.;Nikolaus Plesnila.;Marcel Arnold.;Werner Hacke.;Peter Jüni.;Alexander David Mendelow.;Christian Stapf.;Rustam Al-Shahi Salman.;Jenny Bressan.;Stefanie Lerch.;Arsany Hakim.;Nicolas Martinez-Majander.;Anna Piippo-Karjalainen.;Peter Vajkoczy.;Stefan Wolf.;Gerrit A Schubert.;Anke Höllig.;Michael Veldeman.;Roland Roelz.;Andreas Gruber.;Philip Rauch.;Dorothee Mielke.;Veit Rohde.;Thomas Kerz.;Eberhard Uhl.;Enea Thanasi.;Hagen B Huttner.;Bernd Kallmünzer.;L Jaap Kappelle.;Wolfgang Deinsberger.;Christian Roth.;Robin Lemmens.;Jan Leppert.;Jose L Sanmillan.;Jonathan M Coutinho.;Katharina A M Hackenberg.;Gernot Reimann.;Mikael Mazighi.;Claudio L A Bassetti.;Heinrich P Mattle.;Andreas Raabe.;Urs Fischer.; .
来源: Lancet. 2024年403卷10442期2395-2404页
It is unknown whether decompressive craniectomy improves clinical outcome for people with spontaneous severe deep intracerebral haemorrhage. The SWITCH trial aimed to assess whether decompressive craniectomy plus best medical treatment in these patients improves outcome at 6 months compared to best medical treatment alone.

112. Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation.

作者: Victor Tumukunde.;Melissa M Medvedev.;Cally J Tann.;Ivan Mambule.;Catherine Pitt.;Charles Opondo.;Ayoub Kakande.;Ruth Canter.;Yiga Haroon.;Charity Kirabo-Nagemi.;Andrew Abaasa.;Wilson Okot.;Fredrick Katongole.;Raymond Ssenyonga.;Natalia Niombi.;Carol Nanyunja.;Diana Elbourne.;Giulia Greco.;Elizabeth Ekirapa-Kiracho.;Moffat Nyirenda.;Elizabeth Allen.;Peter Waiswa.;Joy E Lawn.; .
来源: Lancet. 2024年403卷10443期2520-2532页
Preterm birth is the leading cause of death in children younger than 5 years worldwide. WHO recommends kangaroo mother care (KMC); however, its effects on mortality in sub-Saharan Africa and its relative costs remain unclear. We aimed to compare the effectiveness, safety, costs, and cost-effectiveness of KMC initiated before clinical stabilisation versus standard care in neonates weighing up to 2000 g.

113. Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK.

作者: Rebecca L Gould.;Christopher J McDermott.;Benjamin J Thompson.;Charlotte V Rawlinson.;Matt Bursnall.;Mike Bradburn.;Pavithra Kumar.;Emily J Turton.;David A White.;Marc A Serfaty.;Christopher D Graham.;Lance M McCracken.;Laura H Goldstein.;Ammar Al-Chalabi.;Richard W Orrell.;Tim Williams.;Rupert Noad.;Idris Baker.;Christina Faull.;Thomas Lambert.;Suresh K Chhetri.;John Ealing.;Anthony Hanratty.;Aleksandar Radunovic.;Nushan Gunawardana.;Gail Meadows.;George H Gorrie.;Tracey Young.;Vanessa Lawrence.;Cindy Cooper.;Pamela J Shaw.;Robert J Howard.; .
来源: Lancet. 2024年403卷10442期2381-2394页
Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Acceptance and Commitment Therapy (ACT) is a psychological therapy incorporating acceptance, mindfulness, and behaviour change techniques. We aimed to evaluate the effectiveness of ACT plus usual care, compared with usual care alone, for improving quality of life in people with motor neuron disease.

114. Building global preparedness for avian influenza.

作者: Noah Kojima.;Cornelia Adlhoch.;Oriol Mitja.;Vu Quoc Dat.;Andres G Lescano.;Jeffrey D Klausner.
来源: Lancet. 2024年403卷10443期2461-2465页

115. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.

作者: Martin Dreyling.;Jeanette Doorduijn.;Eva Giné.;Mats Jerkeman.;Jan Walewski.;Martin Hutchings.;Ulrich Mey.;Jon Riise.;Marek Trneny.;Vibeke Vergote.;Ofer Shpilberg.;Maria Gomes da Silva.;Sirpa Leppä.;Linmiao Jiang.;Stephan Stilgenbauer.;Andrea Kerkhoff.;Ron D Jachimowicz.;Melania Celli.;Georg Hess.;Luca Arcaini.;Carlo Visco.;Tom van Meerten.;Stefan Wirths.;Pier Luigi Zinzani.;Urban Novak.;Peter Herhaus.;Fabio Benedetti.;Kristina Sonnevi.;Christine Hanoun.;Matthias Hänel.;Judith Dierlamm.;Christiane Pott.;Wolfram Klapper.;Döndü Gözel.;Christian Schmidt.;Michael Unterhalt.;Marco Ladetto.;Eva Hoster.
来源: Lancet. 2024年403卷10441期2293-2306页
Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT.

116. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.

作者: Andrew J Shattock.;Helen C Johnson.;So Yoon Sim.;Austin Carter.;Philipp Lambach.;Raymond C W Hutubessy.;Kimberly M Thompson.;Kamran Badizadegan.;Brian Lambert.;Matthew J Ferrari.;Mark Jit.;Han Fu.;Sheetal P Silal.;Rachel A Hounsell.;Richard G White.;Jonathan F Mosser.;Katy A M Gaythorpe.;Caroline L Trotter.;Ann Lindstrand.;Katherine L O'Brien.;Naor Bar-Zeev.
来源: Lancet. 2024年403卷10441期2307-2316页
WHO, as requested by its member states, launched the Expanded Programme on Immunization (EPI) in 1974 to make life-saving vaccines available to all globally. To mark the 50-year anniversary of EPI, we sought to quantify the public health impact of vaccination globally since the programme's inception.

117. Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.

作者: Frank A Proudlock.;Michael Hisaund.;Gail Maconachie.;Eleni Papageorgiou.;Ali Manouchehrinia.;Annegret Dahlmann-Noor.;Payal Khandelwal.;Jay Self.;Christina Beisse.;Irene Gottlob.; .
来源: Lancet. 2024年403卷10438期1766-1778页
Amblyopia, the most common visual impairment of childhood, is a public health concern. An extended period of optical treatment before patching is recommended by the clinical guidelines of several countries. The aim of this study was to compare an intensive patching regimen, with and without extended optical treatment (EOT), in a randomised controlled trial.

118. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.

作者: Ikechukwu Adigweme.;Mohammed Yisa.;Michael Ooko.;Edem Akpalu.;Andrew Bruce.;Simon Donkor.;Lamin B Jarju.;Baba Danso.;Anthony Mendy.;David Jeffries.;Anne Segonds-Pichon.;Abdoulie Njie.;Stephen Crooke.;Elina El-Badry.;Hilary Johnstone.;Michael Royals.;James L Goodson.;Mark R Prausnitz.;Devin V McAllister.;Paul A Rota.;Sebastien Henry.;Ed Clarke.
来源: Lancet. 2024年403卷10439期1879-1892页
Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children.

120. HIV among refugee youth in Uganda: unmasking the crisis.

作者: Nhial T Tutlam.;Samuel Kizito.;Tewodros W Liyew.;Fred M Ssewamala.
来源: Lancet. 2024年403卷10436期1536-1537页
共有 5672 条符合本次的查询结果, 用时 7.7570398 秒